Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset still's disease

Abstract

Objective. S100A8/A9, follistatin-like protein 1, and interleukin 18 (IL-18) have been suggested as biomarkers of disease activity in patients with systemic juvenile idiopathic arthritis or adult-onset Still'sdisease (AOSD). We investigated the clinical significance of these factors in AOSD.Methods. Blood samples were collected from 36 patients with AOSD, 40 patients with rheumatoidarthritis (RA), and 33 healthy controls. Of the patients with AOSD, followup samples were collectedfrom 16 patients after resolution of disease activity.Results. Serum levels of S100A8/A9 (11.77 ± 8.84 μg/ml) in AOSD patients were higher than thosein RA patients (3.53 ± 3.43 μg/ml; p < 0.001) and controls (2.49 ± 1.83 μg/ml; p < 0.001). Follistatin-like protein 1 levels in AOSD were not different from those in RA and controls. IL-18 levels in AOSD (7560.3 ± 7577.6 pg/ml) were higher than those in RA (217.7 ± 292.1 pg/ml; p < 0.001) and controls (139.2 ± 86.2 pg/ml; p < 0.001). The sensitivity and specificity of IL-18 for diagnosing AOSD was highest with a cutoff value of 366.1 pg/ml. Serum S100A8/A9 correlated with leukocyte count, erythrocyte sedimentation rate, C-reactive protein, ferritin, and systemic disease score; however, IL-18 correlated only with ferritin and systemic disease score. S100A8/A9 was decreased after disease activity was resolved in followup of AOSD patients (9.96 ± 7.35 μg/ml in active AOSD vs 3.6 ± 4.77 μg/ml in resolved cases; p = 0.001). The change of S100A8/A9 was well correlated with that of systemic disease score. Conclusion. The data suggest that serum S100A8/A9 may be a useful biomarker for evaluating disease activity in patients with AOSD. The Journal of Rheumatology Copyright © 2012. All rights reserved.